The Path of Least Resistance: Repositioned Drugs Surpass New Brands

October 24, 2012Media coverage

Article by PharmExec’s Clark Herman on the 505(b)(2) pathway for drug approval … Aris Persidis, president and co-founder of Biovista, a company focused on the 505(b)(2), adds, “In addition, the first to file patent regulations that will take effect in the US next year are making companies realize that they may be susceptible to competitors … Read More

Train: CFIDS INNOVATOR SPOTLIGHT

August 10, 2012Media coverage

Q&A with K. Kimberly McCleary President & CEO The CFIDS Association of America A 2011 article in The Scientist alerted Suzanne to companies applying informatics to drug repurposing. One of them, Biovista, applied to our 2011 funding opportunity and its proposal to identify non-obvious drug therapies for CFS scored well for scientific and strategic merit. … Read More

Research 1st: Repurposing Old Drugs for CFS

June 15, 2012Media coverage

Biovista and its VP for Drug Discovery, Dr. Spyros Deftereos, MD, are featured in an online article in relation to CFIDS Association’s Research Institute Without Walls (RIWW) … The process of drug repurposing, also called “drug repositioning,” can slash the time and cost to bring new therapies to the patients who need them most, says … Read More

Bioworld: Biotech Taps High Tech for Ideas from Start-Up to Finish

May 14, 2012Media coverage

Article on BioWorld by Trista Morrison Biotech firms have long borrowed ideas from the high tech world. The venture-backed start-up business model on which the entire biotech industry is based came from high tech, and it has served both industries well despite their very different timelines and cost structures. Even so, current capital constraints have … Read More